Number of entity's patents that another entity has allegedly infringed.

No definition available.

Name:	us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of claims dismissed.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingencyClaimsDismissedNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The value (monetary amount) of the award the plaintiff seeks in the legal matter.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

+ Details

Name:	us-gaap_LossContingencyDamagesSoughtValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the period from receipt of certification notice until which FDA approval of ANDA will be stayed.

+ References

No definition available.

+ Details

Name:	vvus_PeriodOfStayOfFdaApprovalOfAndaFromReceiptOfCertificationNotice
Namespace Prefix:	vvus_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Period prior to expiration notice of the last to expire of patents-in-suit

+ References

No definition available.

+ Details

Name:	vvus_PeriodPriorToExpirationNoticeOfLastToExpireOfPatentsInSuit
Namespace Prefix:	vvus_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_LitigationCaseAxis=vvus_ThirdParagraphIvCertificationNoticeFromActavisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=vvus_SecondParagraphIvCertificationNoticeFromActavisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=vvus_ParagraphIvCertificationNoticeFromTevaPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=vvus_FederalLeaveToAmendClaimsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=vvus_CaliforniaPrejudiceClaimsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=vvus_StendraAndaLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=vvus_QsymiaAndaLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=vvus_ActavisLaboratoriesFlMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=vvus_ShareholderDerivativeLawsuitMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=vvus_QsymiaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

LEGAL MATTERS (Details) $ in Millions								12 Months Ended
LEGAL MATTERS (Details) $ in Millions	Jan. 03, 2017	Aug. 05, 2015 item	Jul. 07, 2015 item	Jun. 18, 2015 item	Mar. 05, 2015	Jan. 21, 2015 item	Mar. 27, 2014 USD ($)	Dec. 31, 2014
Third Paragraph IV Certification Notice from Actavis Member
LEGAL MATTERS
Number of patents-in-suit			2
Second Paragraph IV Certification Notice from Actavis Member
LEGAL MATTERS
Number of patents-in-suit						2
Paragraph IV Certification Notice from Teva Pharmaceuticals Member
LEGAL MATTERS
Number of patents-in-suit		2
Period of stay of FDA approval of ANDA from receipt of certification notice					30 months
Federal Leave To Amend Claims Member
LEGAL MATTERS
Loss Contingency, Claims Dismissed, Number				2
California Prejudice Claims Member
LEGAL MATTERS
Loss Contingency, Claims Dismissed, Number				7
STENDRA ANDA Litigation member
LEGAL MATTERS
Period prior to expiration notice of the last to expire of patents-in-suit	180 days
Qsymia ANDA Litigation \| Actavis Laboratories FL
LEGAL MATTERS
Period of stay of FDA approval of ANDA from receipt of certification notice								30 months
Shareholder derivative lawsuit \| Minimum \| Qsymia
LEGAL MATTERS
Amount of damages sought \| $							$ 2.8